Limited information on all drugs listed; this chart will be regularly updated as new data emerges. Drugs listed as having a “low” penetrability may have no penetrability at all in patients with normal blood-brain barrier. Very limited data on newer drugs such as etravirine, raltegravir and maraviroc suggests that these agents have limited penetration into the CNS.
